Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s share price traded down 7.8% during trading on Tuesday . The company traded as low as $25.86 and last traded at $26.07, with a volume of 459,939 shares traded. The stock had previously closed at $28.29.
A number of equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday. BTIG Research upgraded shares of Accelerate Diagnostics from a “neutral” rating to a “buy” rating in a research report on Thursday, August 25th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $25.33.
The stock’s 50-day moving average price is $23.21 and its 200-day moving average price is $16.70. The stock’s market cap is $1.37 billion.
In other news, Director Jack W. Schuler bought 90,147 shares of Accelerate Diagnostics stock in a transaction dated Thursday, June 30th. The shares were acquired at an average price of $13.95 per share, with a total value of $1,257,550.65. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 51.40% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the stock. BlackRock Group LTD increased its stake in shares of Accelerate Diagnostics by 58.0% in the first quarter. BlackRock Group LTD now owns 11,022 shares of the company’s stock valued at $159,000 after buying an additional 4,047 shares in the last quarter. HighTower Advisors LLC bought a new position in Accelerate Diagnostics during the second quarter valued at approximately $188,000. American International Group Inc. increased its position in Accelerate Diagnostics by 5.3% in the second quarter. American International Group Inc. now owns 13,263 shares of the company’s stock valued at $191,000 after buying an additional 663 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in Accelerate Diagnostics by 11.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,898 shares of the company’s stock valued at $229,000 after buying an additional 1,580 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Accelerate Diagnostics by 25,550.8% in the second quarter. JPMorgan Chase & Co. now owns 16,673 shares of the company’s stock valued at $240,000 after buying an additional 16,608 shares in the last quarter. 35.62% of the stock is currently owned by institutional investors and hedge funds.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.